Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

National Heart, Lung and Blood Institutes funds multi-year project

Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) will receive $10 million over the next 6 years to find the genetic causes of congenital heart disease.

28 Oct 2009

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage. Researchers and doctors remain puzzled as to what causes the wide range of reaction to Prozac and similar antidepressants.

28 Oct 2009

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement allowing Eli Lilly and Company (NYSE: LLY) select access to research from its osteoarthritis genomic biomarker program

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

Barrett's esophagus patients are at no greater risk of dying than the rest of the population

New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, (http://www.mayoclinic.org/barretts-esophagus/) which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology (http://www.acg.gi.org/) (ACG) Annual Meeting in San Diego.

27 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Obese patients less likely to achieve cholesterol and blood pressure control

Obese patients taking medications to lower their blood pressure and cholesterol levels are less likely to reach recommended targets for these cardiovascular disease risk factors than their normal weight counterparts, according to new research presented at the 2009 Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society and the Heart and Stroke Foundation of Canada.

26 Oct 2009

Scientists discover new way to help save lives threatened by traumatic injuries

A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.

26 Oct 2009

$Cardiovascular disease may increase hip fracture incidence$

Cardiovascular disease may increase hip fracture incidence

A study that includes twins finds that the risk of hip fracture was significantly increased following a diagnosis of cardiovascular disease (CVD), with analysis also suggesting a genetic predisposition to the development of CVD and fractures, according to a study in the October 21 issue of JAMA.

26 Oct 2009

Dr. Shelagh Coutts receives award for developing new brain scan

Award-winning neurologist Dr. Shelagh Coutts is on the fast track of developing new brain scanning techniques for rapid and effective diagnosis of mini-strokes.

26 Oct 2009

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

A new curriculum called The Great Diseases will bring real-world biomedical research to students in three Boston high schools. The result of a collaboration between scientists from Tufts University School of Medicine and teachers from the Boston Public Schools, the curriculum presents current threats to global health through laboratory learning, multimedia, and case-based studies

24 Oct 2009

Cardiac Network announces incubation agreement with Global Private Funding

Cardiac Network, Inc., a leader in advanced mobile medical monitoring, announced today that it has entered into a Business Incubation Services agreement with Global Private Funding, Inc. (Global), a private equity-based lender.

24 Oct 2009

Learn to recognise stroke symptoms and take action: World Stroke Organization

The theme of this year's World Stroke Day on 29th October is "What can I do?". As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

24 Oct 2009

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants’ proposed generic products until the last to expire of the infringed patents, which is 2022.

24 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009.

23 Oct 2009

Quality of U.S. health care was virtually stagnant in 2008, says NCQA report

A report released today by the National Committee for Quality Assurance (NCQA) finds that the quality of U.S. health care was virtually stagnant in 2008, a disturbing slowdown after a decade of improvements. The across-the-board trend was seen in care provided to people with private insurance coverage as well as in Medicare and Medicaid.

23 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

National Heart, Lung and Blood Institutes funds multi-year project

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

Barrett's esophagus patients are at no greater risk of dying than the rest of the population

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Obese patients less likely to achieve cholesterol and blood pressure control

Scientists discover new way to help save lives threatened by traumatic injuries

Cardiovascular disease may increase hip fracture incidence

Dr. Shelagh Coutts receives award for developing new brain scan

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

Cardiac Network announces incubation agreement with Global Private Funding

Learn to recognise stroke symptoms and take action: World Stroke Organization

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Shire announces new pharmacokinetic data of ADHD medication

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

Quality of U.S. health care was virtually stagnant in 2008, says NCQA report

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

KemPharm commences KP106 Phase 1 clinical trial for ADHD

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in